Immunomodulatory properties of characellide A on human peripheral blood mononuclear cells
© 2021. The Author(s)..
Marine sponges and their associated microbiota are multicellular animals known to produce metabolites with interesting pharmacological properties playing a pivotal role against a plethora of pathologic disorders such as inflammation, cancer and infections. Characellide A and B belong to a novel class of glycolipopeptides isolated from the deep sea marine sponge Characella pachastrelloides. In this study, we have evaluated the effects of characellide A and B on cytokine and chemokine release from human peripheral blood mononuclear cells (PBMC). Characellide A induces a concentration- and time-dependent CXCL8, IL-6 and TNF-α release from PBMC. This production is mediated by the induction of gene transcription. Moreover, cytokine/chemokine release induced by characellide A from PBMC is CD1d-dependent because a CD1d antagonist, 1,2-bis(diphenylphosphino)ethane [DPPE]-polyethylene glycolmonomethylether [PEG], specifically inhibits characellide A-induced activation of PBMC. In conclusion, characellide A is a novel modulator of adaptative/innate immune responses. Further studies are needed to understand its potential pharmacological application.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Inflammopharmacology - 29(2021), 4 vom: 09. Aug., Seite 1201-1210 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Marcella, Simone [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biological Factors |
|---|
| Anmerkungen: |
Date Completed 31.12.2021 Date Revised 22.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10787-021-00836-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327876956 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327876956 | ||
| 003 | DE-627 | ||
| 005 | 20231225201743.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10787-021-00836-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1092.xml |
| 035 | |a (DE-627)NLM327876956 | ||
| 035 | |a (NLM)34241784 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Marcella, Simone |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunomodulatory properties of characellide A on human peripheral blood mononuclear cells |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.12.2021 | ||
| 500 | |a Date Revised 22.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a Marine sponges and their associated microbiota are multicellular animals known to produce metabolites with interesting pharmacological properties playing a pivotal role against a plethora of pathologic disorders such as inflammation, cancer and infections. Characellide A and B belong to a novel class of glycolipopeptides isolated from the deep sea marine sponge Characella pachastrelloides. In this study, we have evaluated the effects of characellide A and B on cytokine and chemokine release from human peripheral blood mononuclear cells (PBMC). Characellide A induces a concentration- and time-dependent CXCL8, IL-6 and TNF-α release from PBMC. This production is mediated by the induction of gene transcription. Moreover, cytokine/chemokine release induced by characellide A from PBMC is CD1d-dependent because a CD1d antagonist, 1,2-bis(diphenylphosphino)ethane [DPPE]-polyethylene glycolmonomethylether [PEG], specifically inhibits characellide A-induced activation of PBMC. In conclusion, characellide A is a novel modulator of adaptative/innate immune responses. Further studies are needed to understand its potential pharmacological application | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CD1d | |
| 650 | 4 | |a IL-6 | |
| 650 | 4 | |a LPS | |
| 650 | 4 | |a Simplexide | |
| 650 | 4 | |a TNF-α | |
| 650 | 7 | |a Biological Factors |2 NLM | |
| 650 | 7 | |a Immunomodulating Agents |2 NLM | |
| 650 | 7 | |a Inflammation Mediators |2 NLM | |
| 700 | 1 | |a Afoullouss, Sam |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Olivier P |e verfasserin |4 aut | |
| 700 | 1 | |a Allcock, A Louise |e verfasserin |4 aut | |
| 700 | 1 | |a Murphy, Paul V |e verfasserin |4 aut | |
| 700 | 1 | |a Loffredo, Stefania |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Inflammopharmacology |d 1996 |g 29(2021), 4 vom: 09. Aug., Seite 1201-1210 |w (DE-627)NLM090686616 |x 1568-5608 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2021 |g number:4 |g day:09 |g month:08 |g pages:1201-1210 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10787-021-00836-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2021 |e 4 |b 09 |c 08 |h 1201-1210 | ||